Literature DB >> 35310866

Expected response to the additional third dose of COVID-19 vaccine based on different complete standard vaccination background.

Sora Yasri1, Viroj Wiwanitkit2.   

Abstract

COVID-19 vaccination is proven useful for primary prevention against COVID-19. Classically, two doses of vaccine are required. After complete vaccination, there might be a decline in immunity level. When there is a new emerging variant and a possible decline of immunity in general people after standard mass vaccination, many scientists propose ideas for the additional third dose vaccination. The effectiveness of the third vaccine still unknown, therefore any studies on its effectiveness are interesting. Additionally, there are also many new ideas for using a new type of COVID-19 crossing to the previous completely vaccinated one. In this study, the authors use a clinical model technique for estimating of response to the additional third dose of COVID-19 vaccine based on different complete standard vaccination background. IJPPP
Copyright © 2022.

Entities:  

Keywords:  COVID-19; dose; third; vaccine

Year:  2022        PMID: 35310866      PMCID: PMC8918603     

Source DB:  PubMed          Journal:  Int J Physiol Pathophysiol Pharmacol        ISSN: 1944-8171


  9 in total

1.  Covid-19: Vaccine brands can be mixed in "extremely rare occasions," says Public Health England.

Authors:  Elisabeth Mahase
Journal:  BMJ       Date:  2021-01-04

2.  Covid-19: Third vaccine dose boosts immune response but may not be needed, say researchers.

Authors:  Elisabeth Mahase
Journal:  BMJ       Date:  2021-06-29

3.  Early Immunogenicity and Safety of the Third Dose of BNT162b2 Messenger RNA Coronavirus Disease 2019 Vaccine Among Adults Older Than 60 Years: Real-World Experience.

Authors:  Mayan Gilboa; Michal Mandelboim; Victoria Indenbaum; Yaniv Lustig; Carmit Cohen; Galia Rahav; Keren Asraf; Sharon Amit; Hanaa Jaber; Ital Nemet; Limor Kliker; Erez Bar-Haim; Ella Mendelson; Ram Doolman; Carmit Rubin; Gili Regev-Yochay; Yitshak Kreiss
Journal:  J Infect Dis       Date:  2022-03-02       Impact factor: 5.226

4.  New COVID-19 Vaccines, Its Cost and Shelf Life: A Cost Effectiveness Analysis.

Authors:  Pathum Sookaromdee; Viroj Wiwanitkit
Journal:  Arch Med Res       Date:  2020-12-23       Impact factor: 2.235

Review 5.  COVID-19 vaccine: where are we now and where should we go?

Authors:  Saman Soleimanpour; Atieh Yaghoubi
Journal:  Expert Rev Vaccines       Date:  2021-02-17       Impact factor: 5.217

6.  Effectiveness of a third dose of the BNT162b2 mRNA COVID-19 vaccine for preventing severe outcomes in Israel: an observational study.

Authors:  Noam Barda; Noa Dagan; Cyrille Cohen; Miguel A Hernán; Marc Lipsitch; Isaac S Kohane; Ben Y Reis; Ran D Balicer
Journal:  Lancet       Date:  2021-10-29       Impact factor: 79.321

  9 in total
  2 in total

1.  Expected cost effectiveness of the fourth dose of COVID-19 vaccine against the omicron variant of COVID-19: a preliminary report.

Authors:  Rujittika Mungmunpuntipantip; Viroj Wiwanitkit
Journal:  Int J Physiol Pathophysiol Pharmacol       Date:  2022-08-15

2.  Third dose of mRNA COVID-19 vaccine and response: Correspondence.

Authors:  Pathum Sookaromdee; Viroj Wiwanitkit
Journal:  Liver Int       Date:  2022-07-30       Impact factor: 8.754

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.